Chemotherapy in thymic neoplasms

Pier Franco Conte, Fausto Barbieri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Thymic neoplasms are chemotherapy-sensitive tumors with a 30-50% 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).

Original languageEnglish
Title of host publicationThymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features
PublisherSpringer Milan
Pages225-228
Number of pages4
ISBN (Print)9788847008274
DOIs
Publication statusPublished - 2008

Fingerprint

Thymus Neoplasms
Ifosfamide
Etoposide
Doxorubicin
Cisplatin
Adrenal Cortex Hormones
Drug Therapy
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Conte, P. F., & Barbieri, F. (2008). Chemotherapy in thymic neoplasms. In Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features (pp. 225-228). Springer Milan. https://doi.org/10.1007/978-88-470-0828-1_26

Chemotherapy in thymic neoplasms. / Conte, Pier Franco; Barbieri, Fausto.

Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Springer Milan, 2008. p. 225-228.

Research output: Chapter in Book/Report/Conference proceedingChapter

Conte, PF & Barbieri, F 2008, Chemotherapy in thymic neoplasms. in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Springer Milan, pp. 225-228. https://doi.org/10.1007/978-88-470-0828-1_26
Conte PF, Barbieri F. Chemotherapy in thymic neoplasms. In Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Springer Milan. 2008. p. 225-228 https://doi.org/10.1007/978-88-470-0828-1_26
Conte, Pier Franco ; Barbieri, Fausto. / Chemotherapy in thymic neoplasms. Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Springer Milan, 2008. pp. 225-228
@inbook{e6b5c80acd444b8f84a1332fd4a01495,
title = "Chemotherapy in thymic neoplasms",
abstract = "Thymic neoplasms are chemotherapy-sensitive tumors with a 30-50{\%} 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).",
author = "Conte, {Pier Franco} and Fausto Barbieri",
year = "2008",
doi = "10.1007/978-88-470-0828-1_26",
language = "English",
isbn = "9788847008274",
pages = "225--228",
booktitle = "Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features",
publisher = "Springer Milan",

}

TY - CHAP

T1 - Chemotherapy in thymic neoplasms

AU - Conte, Pier Franco

AU - Barbieri, Fausto

PY - 2008

Y1 - 2008

N2 - Thymic neoplasms are chemotherapy-sensitive tumors with a 30-50% 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).

AB - Thymic neoplasms are chemotherapy-sensitive tumors with a 30-50% 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).

UR - http://www.scopus.com/inward/record.url?scp=84891440787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891440787&partnerID=8YFLogxK

U2 - 10.1007/978-88-470-0828-1_26

DO - 10.1007/978-88-470-0828-1_26

M3 - Chapter

SN - 9788847008274

SP - 225

EP - 228

BT - Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features

PB - Springer Milan

ER -